FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.

Michael Millward,Hui K. Gan,Anthony M. Joshua,James Kuo,A. Prawira,Gary Edward Richardson,Susannah D. Barbee,Sandeep P. Inamdar,Kristen L. Pierce,Mona Qureshi,Lisa G. Horvath

FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.

2019

Michael Millward
Hui K. Gan
Anthony M. Joshua
James Kuo
A. Prawira
Gary Edward Richardson
Susannah D. Barbee
Sandeep P. Inamdar
Kristen L. Pierce
Mona Qureshi
Lisa G. Horvath

TPS42Background: Despite recent advances in immunotherapy, many patients with advanced solid tumors are refractory to available therapies or eventually relapse. Novel immune therapies are needed wi...

Keywords:

Pathology
Oncology
Internal medicine
Medicine
CD80
Immunotherapy
immune therapy
Refractory
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations